Scientists discover new compounds to target muscular dystrophy
The revelation that champion marathon runner Kerryn McCann did nothing for months after discovering a lump in her breast, is a stark warning to women to heed any changes they notice in their breasts and seek medical advice. According to the National Breast and Ovarian Cancer Centre (NBOCC), the dual Commonwealth marathon gold medallist and
Full Post: Untimely death of Kerryn McCann a stark warning
Scientists have identified a promising set of new compounds in the fight against muscular dystrophy.
Using a drug-discovery technique in which molecules compete against each other for access to the target - the strand of toxic RNA that causes the most common form of muscular dystrophy in adults - a team at the University of Rochester Medical Center has identified several compounds that, in the laboratory, block the unwanted coupling of two molecules that is at the root of the disease.
The work was published online November 7 by the Journal of the American Chemical Society.
“This discovery gives us, for the first time, a molecule that targets the wayward RNA at the root of myotonic muscular dystrophy,” said Benjamin Miller, Ph.D., the chemist who led the study. “This is a first step toward developing a drug-like molecule that perhaps could be used someday to treat the disease. This lead molecule provides a framework for moving forward.”
Miller leads a team that is developing small molecules that target small strands of RNA. He notes that drugs more commonly target proteins or DNA, but that RNA offers an alluring target for some diseases.
“The drug discovery field really is wide open when it comes to RNA, which is a very difficult molecule to target,” said Miller, who is an associate professor in the departments of Dermatology, Biomedical Engineering, and Biochemistry and Biophysics.
The work is the latest in a series of developments in which a Rochester team led by neurologist Charles Thornton, M.D., has shown how a genetic flaw creates the symptoms of myotonic dystrophy, which affects about 35,000 Americans.
“This is an important first step toward developing a drug treatment for myotonic dystrophy. The message from our patients is loud and clear - push this forward as fast as possible,” said Thornton, who is co-director of University’s Neuromuscular Disease Center.
The disease is marked by progressive muscle weakness, and eventually many patients have difficulty walking, swallowing, and breathing. The disease also affects the eyes, the heart, and the brain. Currently there is no treatment.
The genetic mistake involves a repeated sequence of three chemical bases. Healthy people have anywhere from five to 30 copies of the “triplet repeat” known as CUG on chromosome 19, but people with the disease typically have hundreds or thousands of copies, a kind of molecular stutter. These extra copies become part of large, faulty messenger RNA molecules that can mistakenly glom onto proteins and knockout their normal function.
Earlier this decade, Thornton’s team discovered that the faulty messenger RNA has a toxic effect on muscle and heart tissue. The team found that the toxic RNA binds tightly to a crucial protein known as “muscle blind” or MBNL1 and prevents that protein from performing its usual function, ultimately leading to the muscle symptoms of muscular dystrophy.
The goal for doctors is to free up MBNL1 in cells so that it can go about its normal activities, which include building proper chloride channels that are central to normal muscle function.
So Miller set out to free MBNL1 by designing an experiment to search for a small molecule that would sop up extra CUG copies. Using a technique known as dynamic combinatorial chemistry, Miller mixed two sets of 150 compounds, one on polymer beads and the other in solution, and let the components link up with each other in a kind of molecular dance, amid a sea of CUG “triplet repeat” RNA strands. The technique, which Miller helped to pioneer more than a decade ago, allowed him to simultaneously analyze how effectively more than 11,000 molecular combinations could bind to the target CUG RNA strand.
Miller’s team sorted out which combinations muscled out the others for access to RNA strands and held most tightly onto them. The team then took the best performers and put them in a solution containing both CUG repeat RNA and MBNL1. Miller’s molecules were able to break up the interaction between the two, with the best molecules freeing up to half the MBNL1 - the precise step that needs to be taken in patients with the disease.
The team is continuing its work, further refining the molecules in an attempt to find one that frees MBNL1 even more effectively.
In addition to Miller and Thornton, other authors of the paper included former graduate student Peter Gareiss, Ph.D., who is now at Yale; post-doctoral research associate Krzysztof Sobczak, Ph.D.; former graduate student Brian McNaughton, Ph.D., now at Harvard; and graduate student Prakash Palde. The work was funded in part by the University’s Muscular Dystrophy Cooperative Research Center, which is funded by the National Institutes of Health.
Current research suggests laminin, a protein that helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy. The related report by Rooney et al, “Laminin-111 restores regenerative capacity in a mouse model for alpha 7 integrin congenital myopathy,” appears in the January 2009 issue of The American Journal of Pathology. Muscular dystrophy
Full Post: Laminin-111 shows potential for congenital muscular dystrophy
Just as the emotions it represents are dynamic, the heart’s development requires dynamic shifts in proteins that prompt alternative spicing, a mechanism that allows a given gene to program the cell to make several proteins, said a group of researchers at Baylor College of Medicine in a report that appears online in the journal Proceedings
Full Post: Alternative splicing proteins prompt heart development
Mutations in the nuclear intermediate filament lamin A/C (LMNA) gene are associated with Emery-Dreifuss muscular dystrophy, but cause the disease by unknown mechanisms. Méjat et al. show that one mechanism involves the disruption of neuromuscular junctions. The study will appear online on Monday, January 5, 2009 and in the January 12, 2009 print issue of
Full Post: How loss or mutation of LMNA gene causes Emery-Dreifuss muscular dystrophy
A protein that was first identified for playing a key role in regulating normal heart rhythms also appears to be significant in helping muscle cells survive the forces of muscle contraction. The clue was a laboratory mouse that seemed to have a form of muscular dystrophy. A group of proteins called ankyrins, or anchor proteins,
Full Post: Proteins called ankyrins required to prevent muscular dystrophy
The only known genetic risk factor for Alzheimer’s disease slows down the brain’s ability to export a toxic protein known as amyloid-beta that is central to the damage the disease causes, scientists have found. The research, published Nov. 13 by the Journal of Clinical Investigation, provides new clues into the workings of a protein known
Full Post: Alzheimer’s gene slows brain’s ability to export toxic protein